Who
Ari Maizel
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Axsome Therapeutics.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $5.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Feb 2025
- Last trade
- 22 Apr 2026
- Last filed
- 23 Apr 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $530K7,500 at $70.73 | filing |
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M7,500 at $182.42 | filing |
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $530K7,500 at $70.73 | filing |
| 22 Apr 2026filed 23 Apr 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M7,500 at $182.42 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,224 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,224 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,385 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,385 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $530K7,500 at $70.73 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M7,500 at $184.44 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $530K7,500 at $70.73 | filing |
| 21 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M7,500 at $184.44 | filing |
| 24 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,740 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,816 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,740 at $0.00 | filing |
News
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?AXSM · fool.com · 8 Oct 2026
0 headlines in the last 90 days name Ari Maizel; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.